Join to View Full Profile
55 Fruit St Yaw 9Brain Tumor Center Neuro-OncologyBoston, MA 02114
Phone+1 617-724-8770
Fax+1 617-724-8769
Dr. Plotkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Massachusetts General HospitalFellowship, Neuro-Oncology, 2002 - 2003
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1999 - 2002
Tulane UniversityInternship, Internal Medicine, 1998 - 1999- Tulane University School of MedicineClass of 1998
Certifications & Licensure
MA State Medical License 2002 - 2027
FL State Medical License 2024 - 2026
NH State Medical License 2023 - 2025
LA State Medical License 2002 - 2002
American Board of Psychiatry and Neurology Neurology
United council of neurological subspecialtiesNeuro-Oncology
Clinical Trials
- Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 Start of enrollment: 2008 Mar 01
- Concentration and Activity of Lapatinib in Vestibular Schwannomas Start of enrollment: 2009 Jun 01
- Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsChallenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.Eva Dombi, Andrea M Gross, Brigitte C Widemann, Brian D Weiss, Scott R Plotkin
Journal of Clinical Oncology. 2025-03-19 - Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.Joe S Mendez, Adam L Cohen, Midori Eckenstein, Randy L Jensen, Lindsay M Burt
Neuro-Oncology Advances. 2024-11-22 - Expanding therapeutic options for people with NF2-related schwannomatosis: Encouraging results with brigatinib.Scott R Plotkin, Jaishri O Blakeley
Neuro-Oncology. 2024-11-04
Journal Articles
- Increasing Access to Specialty Care for Rare Diseases: A Case Study Using a Foundation Sponsored Clinic Network for Patients with Neurofibromatosis 1, Neurofibromatosi...Scott R Plotkin, Justin T Jordan, BioMed Central
Press Mentions
University of Miami Miller School of Medicine Selected for National NF2 Tumor Clinical TrialJune 1st, 2022
Wayne Biopharma Firm Targeting Rare Genetic Disorders Raises $6MMay 1st, 2020
Antiangiogenesis Treatment Improves Hearing in Some NF2 PatientsJuly 8th, 2009- Join now to see all
Grant Support
- Neurofibromatosis and Schwannomatosis Genes Variant Curation Expert Panel (VCEP)MASSACHUSETTS GENERAL HOSPITAL2024–2027
- Training Program in Nervous System TumorsMASSACHUSETTS GENERAL HOSPITAL2001–2026
- Training Program in Nervous System TumorsMASSACHUSETTS GENERAL HOSPITAL2001–2026
- Training Program in Nervous System TumorsMASSACHUSETTS GENERAL HOSPITAL2001–2026
- Training Program in Nervous System TumorsMASSACHUSETTS GENERAL HOSPITAL2001–2026
- Fetal Alcohol Effects On Blood Brain Barrier TransportNational Institute On Alcohol Abuse And Alcoholism1995–1997
- Fetal Alcohol Effects On Blood Brain Barrier TransportNational Institute On Alcohol Abuse And Alcoholism1994
Professional Memberships
- Member
Industry Relationships
- Co-Founder, NF2 Therapeutics
- Co-Founder, NFlection Therapeutics
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
